Halozyme Therapeutics (NASDAQ:HALO) Director Bernadette Connaughton Sells 1,625 Shares of Stock

Posted by Stanley Muller on Jul 3rd, 2026

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the sale, the director directly owned 42,044 shares of the company’s stock, valued at $3,225,195.24. The trade was a 3.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

On Monday, June 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $66.21, for a total transaction of $107,591.25.
On Friday, May 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00.

Halozyme Therapeutics Price Performance

HALO opened at $79.45 on Friday. The stock has a market cap of $9.42 billion, a P/E ratio of 28.58, a P/E/G ratio of 0.32 and a beta of 0.84. Halozyme Therapeutics, Inc. has a 12 month low of $53.33 and a 12 month high of $82.22. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The company has a fifty day simple moving average of $69.18 and a 200 day simple moving average of $69.35.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same period in the previous year, the company posted $1.11 earnings per share. The company’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on HALO shares. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Finally, Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $81.60.

Get Our Latest Stock Analysis on Halozyme Therapeutics

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Clark Capital Management Group Inc. raised its position in Halozyme Therapeutics by 14.4% during the third quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock worth $14,885,000 after acquiring an additional 25,582 shares in the last quarter. Allworth Financial LP grew its position in shares of Halozyme Therapeutics by 322.5% in the 3rd quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after acquiring an additional 30,331 shares during the period. Element Squared LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $1,193,000. Dimensional Fund Advisors LP increased its stake in shares of Halozyme Therapeutics by 3.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock worth $152,431,000 after purchasing an additional 63,699 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $907,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.